Kunming Pharmaceutical Group boosts net profit 20% despite revenue dip

Kunming Pharmaceutical Group (SSE:600422) reported a net profit attributable to shareholders of CNY 648.08 million for 2024, a 19.86% increase year-over-year, despite a marginal revenue decrease of 0.34% to CNY 8,401.45 million. The company highlighted that profitability has grown significantly due to the successful merger of Huasun Saintfire with strong sales growth for Kunming Zhongya 1381 and 777 formulations. KPC notes that they expect revenues to continue increasing at a double-digit rate. While basic earnings per share increased to CNY 0.86.